For our patient with EWSR1/CREB1 fusion-positive GNET, we selected a combination of immunotherapy and targeted therapy following disease relapse with hepatic and peritoneal metastases. The gene discussed is CREB1; the disease is gastric neuroendocrine tumor, well differentiated, low or intermediate grade.